Conduct a pre-NDA meeting with the FDA for ACER-001
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 15 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- Q2 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“ACER-001 pre-NDA meeting with FDA$: Q2 2021”
What we found
Evidence strength A What the grades mean
The company confirmed in an SEC filing that it completed the pre-NDA meeting for ACER-001 during the second quarter of 2021.
-
A Acer Therapeutics Inc. 8-K filed 2021-08-10
“Following completion of a Q2 2021 pre-NDA meeting with the U.S. Food and Drug Administration (FDA), submitted a New Drug Application (NDA) in August 2021 for ACER-001” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory other
- Indicative materiality
- Medium rules
- Action
- Conduct
- Deliverable
- ACER-001 pre-NDA meeting
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: Subject to additional capital
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Acer Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C069308-022132 · Corrections policy